

REMARKS

Claims 1-28, 30 and 32-36, as amended, appear in this application. Claims 1, 2 and 5-10 were amended to delete subject matter directed to non-elected inventions, and claim 3 was amended to depend from claim 1. Claims 29 and 31 have been cancelled, and claims 11-24, 26-28, 30, 32 and 34-36 are currently withdrawn. No new matter has been introduced.

In response to the restriction requirement made in the office action dated October 20, 2005, Applicants elect, with traverse, the invention of Group III, claims 1-10, 25 and 33, drawn to peptides comprising SEQ ID NO: 11-16, pharmaceutical compositions and diagnostic applications, for prosecution in this application.

It is understood that the method claims of Group XI that are currently withdrawn will be rejoined with the Group III claims upon an allowance of claim 1. In addition, at least the claims of Groups VII and XV, drawn to nucleic acids encoding the peptides of Group III and methods of use thereof; Group XIX, drawn to a vaccine comprising the peptides of Group III; and Group XXIII, drawn to an antibody against the peptides of Group III, should be joined and Examined together with the Group III claims. The reason is that the claims of Groups VII, XV, XIX and XXIII are directed to nucleic acids encoding the peptides of Group III, methods of use thereof, vaccines comprising the peptides of Group III and antibodies against same. Thus, all of these claims have in common the peptides of Group III or nucleic acids encoding same. Certainly, a patentability search for the peptides will identify related vaccines, antibodies and nucleic acids. Therefore, the claims of Groups III, VII, XI, XV, XIX and XXIII of the present invention are not independent and distinct as required to establish restriction, but instead are directed to a single, general inventive concept. Thus, all claims should be considered as being directed to a single invention and be examined together at this time.

It is believed that at least claims 1-10, 25, 27 and 33, drawn to the peptides of Group III, pharmaceutical compositions, diagnostic applications and methods of use for treating cancer, are now in condition for allowance, early notice of which would be appreciated.

Respectfully submitted,

Date

11/17/05



Allan A. Fanucci

(Reg. No. 30,256)

WINSTON & STRAWN LLP
CUSTOMER NO. 28765
(212) 294-3311